Drugs / ImmuniCell®
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02459067 | Dec 2015 → Nov 2018 | melanoma, non-small cell lung carcinoma, renal cell carcinoma | TC Biopharm | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ImmuniCell | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02459067 ↗ |
| Modality | Cell therapy | “Autologous γδ T Lymphocytes” NCT02459067 ↗ |